The abstract is read at the publisher; the summary is JClub's.
CD16HSC-NKT stem cell–derived invariant natural killer T cells enhanced monoclonal antibody therapy across diverse tumor models, achieving durable eradication and prolonged survival in xenografts.
- Why it matters: mAb efficacy is limited by weak ADCC, antigen escape, and an immunosuppressive tumor microenvironment, creating a need for an off-the-shelf cellular enhancer.
- What they did: The study engineered allogeneic stem cell–derived invariant NKT cells to express a high-affinity non-cleavable CD16 receptor (CD16HSC-NKT) and tested them with multiple antibodies in hematologic and solid tumor models, including xenografts.
- The result: Antibodies drove CD16HSC-NKT expansion, persistence, and activation in tumors, while CD16HSC-NKT remodeled the TME by depleting CD1d-expressing tumor-associated macrophages and myeloid-derived suppressor cells, with minimal alloreactivity and no graft-versus-host disease or detectable systemic toxicity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.